{"classes":[{"categories":[{"measurements":[{"comment":"The confidence interval could not be calculated from the data of one participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Tumor assessment was performed using mINRC for Participants with Neuroblastoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Neuroblastoma.","id":"OG000","title":"Neuroblastoma"}],"paramType":"MEDIAN","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.","reportingStatus":"POSTED","timeFrame":"From the time of cobimetinib study drug initiation to the first documented disease progression, or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"Progression-Free Survival (PFS) as Determined by the Investigator Using mINRC for Participants With Neuroblastoma (Phase I)","type":"PRIMARY","unitOfMeasure":"Months"}